Company: SXTPW
Filing Date: 2025-02-06
Form Type: 424B5
Source: 0001213900-25-010772
Chunk: 9

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-06
Form: 424B5
Chunk 9
---
,000 reported cases of candidiasis (a type of fungal infection) each year in   
 the United States and up to 1,900 clinical cases of C. auris, for which there are few available treatments.15                
 Since it has broad-spectrum activity against drug-resistant Candida spp in culture, Tafenoquine, has the potential to        
 be a market leading therapy for treatment/prevention of C. auris, and to be added to the standard of care regimens for other 
 Candida infections.16                                                                                                        |

| 10 | This estimate is based                                                                                                                  
 on the observations of Krugeler et al (Emerg Infect Dis 2021;27:616-61) who reported that 476,000 cases of Lyme disease occur           
 in U.S. states where babesiosis is endemic and Krause et. al. (JAMA 1996;275:1657-16602) who reported that 10% of Lyme disease patients 
 are co-infected with babesiosis and that according to Krause et al (AJTMH 2003;6:431-436) fact that about 80% of cases are symptomatic  
 (thus 476,000*10%*80% = 38,000 cases of babesiosis per year).                                                                           |

| 11 | Bloch                                           
 et al Open Forum Infect Dis 2022;9(11):ofac597. |

| 12 | According           
 to IDSA guidelines. |

| 13 | See Krause et al Clin Infect Dis 2024; doi:10.1093/cid/ciae238 and https://ysph.yale.edu/news-article/antimalarial-drug-is-effective-against-tick-borne-infection-babesiosis/. |

| 14 | Marx                           
 et. al., MMWR 2021;70:612-616. |

| 15 | https://www.cdc.gov/fungal/diseases/candidiasis/invasive/statistics.html.; https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html. |

| 16 | Dow                                             
 and Smith New Microb New Infect 2022;45:100964. |

<div align='center'>S-3</div>

| ● | Prevention of fungal                                                                                                                          
 pneumonias. There are up to ~ 91-92,000 new patient cases each year in the United States for which antifungal prophyl